Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar belakang: Systemic Immune-inflammation Index adalah suatu indeks hasil perhitungan antara trombosit (T), neutrofil (N), dan limfosit (L) dengan rumus SII = T × N/L. Retinoblastoma risiko tinggi, diantaranya: Rb bilateral, trilateral, grup D-E pada klasifikasi tumor intraokular berdasarkan International Classification of Retinoblastoma (ICRB), stadium III-IV menurut klasifikasi tumor ekstraokular berdasarkan International Staging System for Retinoblastoma (ISSRB), dan gambaran histologi unfavorable. Tujuan: Mengetahui kemampuan SII sebagai prediktor kesintasan tiga tahun Rb risiko tinggi. Metode: Kohor retrospektif, Agustus – September 2024, di RS Dr. Cipto Mangunkusumo. Hasil: Analisis dilakukan terhadap 157 subjek Rb risiko tinggi antara 2016 – 2024. Titik potong berdasarkan kurva Receiver Operating Characteristic (ROC) dengan nilai maksimal indeks Youden berada pada SII 351,72. Overall survival (OS) dan Event free survival (EFS) Rb risiko tinggi pada 36 bulan, berturut-turut adalah 39,5% (SE±4,5%) dan 38,1% (SE±4,5%). Median OS dan EFS 36 bulan, berturut- turut adalah 17 bulan dan 16 bulan. Nilai SII ≥351,72 memiliki median OS 11 bulan dan adjusted HR (aHR) sebesar 1,98 (p=0,02; IK 95% 1,13 – 3,35). Kesimpulan: SII dapat memprediksi kesintasan Rb risiko tinggi.

---

Background: The Systemic Immune-Inflammation Index (SII) is an index calculated from platelets (T), neutrophils (N), and lymphocytes (L) using the formula SII = T × N/L. High-risk Rb includes bilateral Rb, trilateral Rb, group D-E in the intraocular tumor classification based on the International Classification of Retinoblastoma (ICRB), stage III-IV in the extraocular tumor classification based on the International Staging System for Retinoblastoma (ISSRB), and unfavorable histological features.

Objective: To determine the ability of SII as a predictor of three-year survival in high-risk Rb.

Methods: A retrospective cohort study, from August to September 2024 at Dr. Cipto Mangunkusumo Hospital.

Results: The analysis was conducted on 157 high-risk Rb subjects between 2016 and 2024. The cut-off point based on the Receiver Operating Characteristic (ROC) curve, with the maximum Youden index value, was identified at an SII of 351.72. The overall survival (OS) and event-free survival (EFS) rates at 36 months for high-risk Rb were 39,5% (SE±4,5%) dan 38,1% (SE±4,5%), respectively. The median OS and EFS were 17 months and 16 months, respectively. An SII value ≥351.72 was associated with a median OS of 11 months and adjusted HR (aHR) of 1,98 (p=0,02; 95% CI 1,13 – 3,35).

Conclusion: SII may predict survival in high-risk Rb."

"Latar belakang: Penderita leukemia limfoblastik akut (LLA) akan mengalami perubahan status oksidan dan antioksidan sejak awal diagnosis dan selama kemoterapi. Vitamin E merupakan antikarsinogenik kuat dan berperan besar mencegah kerusakan oksidatif pada struktur sel dan jaringan lewat reaksi pemecahan radikal bebas. Tujuan: Mengetahui pengaruh vitamin E terhadap kadar oksidan, kadar enzim transaminase, dan insiden demam neutropenia pada LLA saat awal dan selesai kemoterapi fase induksi. Metode: Uji klinis acak tersamar ganda yang membandingkan kelompok vitamin E dengan kelompok plasebo pada penderita LLA saat awal dan selesai kemoterapi fase induksi pada bulan Juni-November 2019 di poliklinik Hematologi Onkologi Departemen Ilmu Kesehatan Anak FKUI RSCM Kiara. Hasil: Terdapat peningkatan kadar median MDA saat awal fase induksi dan terjadi penurunan MDA secara bermakna saat selesai fase induksi pada kelompok plasebo. Terdapat peningkatan median enzim transaminase (AST dan ALT) saat awal fase induksi dan terjadi penurunan delta median AST secara bermakna saat selesai fase induksi pada kelompok plasebo. Insiden demam neutropenia (episode) ditemukan hampir sama pada kelompok vitamin E dan kelompok plasebo. Simpulan: Vitamin E tidak terbukti secara bermakna memperbaiki kadar MDA, enzim transaminase, dan insiden demam neutropenia pada penderita LLA fase induksi.

---

Background: Children undergoing treatment for acute lymphoblastic leukemia receive multiagent chemotherapy are associated with free radical production may affect the antioxidant status at diagnosis and during treatment. Vitamin E as an anticarcinogenenic agent play important role to prevent oxidative damage in cell by quenching free radicals.

Aim: To identify effects of vitamin E in oxidant level, serum levels of liver enzymes, and incidence of febrile neutropenia before and after induction phase chemotherapy of ALL.

Methods: A randomized double-blind controlled trial of vitamin E compared with placebo in ALL during induction phase chemotherapy between June-November 2019 at Hematology Oncology clinic, Department of Child Health, Faculty of Medicine, Cipto Mangunkusumo Hospital, Kiara.

Results: The median of MDA level was increase at early induction phase and significantly decrease after induction phase in placebo group. The median of serum levels of liver enzymes (AST and ALT) were increase at early induction phase and the delta median of AST level was significantly decrease after induction phase in placebo group. Incidence of febrile neutropenia (episode) was not much different in vitamin E and placebo group.

Conclusions: Vitamin E not significantly can improve MDA level, serum levels of liver enzymes, and incidence of febrile neutropenia in induction phase of ALL."